Price
Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.
Smart Score
AverageBD is a global medical technology company engaged in the development, manufacture and sale of a broad range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. We provide customer solutions that are focused on improving medication management and patient safety; supporting infection prevention practices; equipping surgical and interventional procedures; improving drug delivery; aiding anesthesiology care; enhancing the diagnosis of infectious diseases and cancers; and advancing cellular research and applications.
In the company’s own words · 10-K filed Nov 25, 2025 · SEC EDGAR
Business segments
Q2 2026 · $1.96BThe company’s own SEC segment disclosure.
- Connected Care$737.0M38%
- Medical Essentials$720.0M37%
- Interventional$294.0M15%
- Bio Pharma Systems$204.0M10%
Becton Dickinson (BDX) reported revenue of $4.98B in Q3 2026 (quarter ended June 30, 2026), up 5.4% from the same quarter a year earlier. That came with a gross margin of 46% and net income of $377M (7.6% of revenue). For the full year FY2025, revenue was $21.8B (+8.2% year on year) and net income $1.68B. Its largest segment in 2026-Q2 was Connected Care at $737M, 38% of the disclosed total, just ahead of Medical Essentials at 37%.
Raw charts
11 series · TTMAs reported to the SEC, without any scoring.
Medical Instruments & Supplies
Ranks #17 of 27 by Smart Score